We are live on
!
Find out more
Axa Portfolio holdings
AUM
$91.9M
1-Year Est. Return
27.41%
This Fund
S&P 500
This Quarter
Est. Return
+5.26%
1 Year Est. Return
+27.41%
3 Year Est. Return
+100.68%
5 Year Est. Return
+129.89%
10 Year Est. Return
+554.73%
AUM
$24B
AUM Growth
+$1.05B
(+4.6%)
Cap. Flow
-$221M
Cap. Flow
% of AUM
-0.92%
Top 10 Holdings %
Top 10 Hldgs %
13.73%
Holding
1,494
New
103
Increased
612
Reduced
406
Closed
115
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$114M |
| 2 |
AET
Aetna Inc
AET
|
+$96.3M |
| 3 |
Travelers Companies
TRV
|
+$94.5M |
| 4 |
CHK
Chesapeake Energy Corporation
CHK
|
+$89M |
| 5 |
Ameren
AEE
|
+$69.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Deutsche Bank
DB
|
+$247M |
| 2 |
Verizon
VZ
|
+$186M |
| 3 |
Medtronic
MDT
|
+$150M |
| 4 |
LO
LORILLARD INC COM STK
LO
|
+$126M |
| 5 |
Johnson Controls International
JCI
|
+$104M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 15.44% |
| 2 | Technology | 14.68% |
| 3 | Financials | 12.75% |
| 4 | Industrials | 11.1% |
| 5 | Energy | 9.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
551
Williams Companies
WMB
$87.6B
| $4.61M | 0.02% |
79,200
| – | – |
|
552
Henry Schein
HSIC
$9.75B
| $4.6M | 0.02% |
98,825
+27,234
| +38% | +$1.25M |
|
|
AEGR
553
DELISTED
Aegerion Pharmaceuticals
AEGR
| $4.58M | 0.02% |
142,823
-8,333
| -6% | -$310K |
|
|
COL
554
DELISTED
Rockwell Collins
COL
| $4.58M | 0.02% |
58,577
+13,177
| +29% | +$1.04M |
|
|
LPNT
555
DELISTED
LifePoint Health, Inc.
LPNT
| $4.56M | 0.02% |
73,392
+13,165
| +22% | +$772K |
|
556
Cadence Design Systems
CDNS
$75.4B
| $4.55M | 0.02% |
260,000
| – | – |
|
|
ELME
557
Elme Communities
ELME
$148M
| $4.54M | 0.02% |
174,960
+125,800
| +256% | +$3.15M |
|
|
UPL
558
DELISTED
Ultra Petroleum Corp. Common Stock
UPL
| $4.52M | 0.02% |
152,286
+150,000
| +6,562% | +$4.26M |
|
|
SVM
559
Silvercorp Metals
SVM
$2.52B
| $4.51M | 0.02% |
2,136,651
| – | – |
|
560
Nektar Therapeutics
NKTR
$2.28B
| $4.5M | 0.02% |
23,404
-941
| -4% | -$166K |
|
561
International Paper
IP
$18B
| $4.49M | 0.02% |
95,162
+4,194
| +5% | +$184K |
|
562
Paychex
PAYX
$42.1B
| $4.46M | 0.02% |
107,395
+32,546
| +43% | +$1.34M |
|
|
SWFT
563
DELISTED
Swift Transportation Company
SWFT
| $4.46M | 0.02% |
176,900
-13,300
| -7% | -$323K |
|
|
GGP
564
DELISTED
GGP Inc.
GGP
| $4.45M | 0.02% |
189,000
+92,000
| +95% | +$2.14M |
|
|
HSTO
565
DELISTED
Histogen Inc. Common Stock
HSTO
| $4.44M | 0.02% |
2,438
+975
| +67% | +$1.3M |
|
566
Compañía de Minas Buenaventura
BVN
$8.44B
| $4.43M | 0.02% |
374,844
| – | – |
|
|
HMSY
567
DELISTED
HMS Holdings Corp.
HMSY
| $4.39M | 0.02% |
215,003
-4,346
| -2% | -$78.3K |
|
|
CTXS
568
DELISTED
Citrix Systems Inc
CTXS
| $4.38M | 0.02% |
87,906
-65,595
| -43% | -$3.15M |
|
569
Terex
TEX
$6.67B
| $4.37M | 0.02% |
106,200
-43,300
| -29% | -$1.76M |
|
570
State Street SPDR S&P Emerging Asia Pacific ETF
GMF
$421M
| $4.34M | 0.02% |
52,429
+10,900
| +26% | +$869K |
|
|
INVX
571
Innovex International
INVX
$2.09B
| $4.33M | 0.02% |
39,588
-146,354
| -79% | -$15.7M |
|
|
COHR
572
DELISTED
Coherent Inc
COHR
| $4.3M | 0.02% |
65,000
| – | – |
|
573
Fortune Brands Innovations
FBIN
$4.77B
| $4.28M | 0.02% |
125,504
-1,303,350
| -91% | -$44.7M |
|
|
INFA
574
DELISTED
INFORMATICA CORP
INFA
| $4.28M | 0.02% |
120,000
+5,000
| +4% | +$184K |
|
|
TESO
575
DELISTED
Tesco Corp
TESO
| $4.27M | 0.02% |
200,000
+120,000
| +150% | +$2.46M |
|
Similar funds
VI
FA
PBCM
CCAM
GBA
AWP
HI
DCA
Axa's Q2 2014 Portfolio in Review
As of Q2 2014, Axa held 1,494 positions worth $24B, up 4.6% from $23B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Axa's Q2 2014 filing shows 103 new, 612 increased, 406 reduced and 115 closed positions. Its largest new stake was Boston Scientific: 4,394,250 shares worth $56.1M. The largest sale was Deutsche Bank, an estimated $247M.
By sector, the portfolio is most concentrated in Healthcare at 15% of assets, down from 16% a quarter earlier, followed by Technology and Financials.
- Axa's largest Q2 2014 buy was Boston Scientific: 4,394,250 shares worth $56.1M.
- Axa added most to Gilead Sciences in Q2 2014, an estimated $114M increase.
- Axa's biggest Q2 2014 reduction was Deutsche Bank, cutting an estimated $247M.
- Axa fully exited OMNICARE INC in Q2 2014, selling an estimated $20.4M.
- Axa's ten largest holdings make up 14% of its $24B portfolio in Q2 2014.
- Axa opened 103 new positions and closed 115 in Q2 2014.
- Axa's portfolio value rose 4.6% quarter-over-quarter to $24B.
Based on Axa's 13F filing for Q2 2014, filed 13 Aug 2014.